1. 1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-65.
2. 2. Mc Ardle BA, Birnie DH, Klein R, et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography? Circ Cardiovasc imaging 2013; 6: 617-26.
3. 3. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014; 4: 1.
4. 4. Yoshinaga K, Manabe O, Ohira H, et al. Focus issue on cardiac sarcoidosis from international congress of nuclear cardiology and cardiac CT (ICNC 12) symposium: improving the detectability of cardiac sarcoidosis-practical aspects of 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-. Ann Nucl Cardiol 2016; 1(1): 87-94.
5. 5. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26: 1538-43.